Formulations and Methods for Treating Symptoms of Menopause
AssigneeKindra Corporation
InventorsHasti Fay Nazemzadeh, Sundeep Singh Gill
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to aqueous topical formulations comprising at least one TRPV1 antagonist and at least one specific plant extract. Also disclosed herein are methods of treating at least one symptom of menopause comprising topically administering an effective amount of the formulations disclosed.
Claims111
An aqueous topical formulation comprising:
- at least one TRPV1 antagonist;
- and
- at least one plant extract chosen from chamomilla recutita flower extract, sapindus trifoliatus fruit extract, aloe leaf juice, cucumber extract, hydrolyzed quinoa, hamamelis virginiana leaf extract, oat kernel extract, oat kernel flour, coconut extract, rosa damascena extract, microalgae extract, akebia quinate extract, rhodosorus marinus extract, Phaeodactylum tricornutum extract, conifer extract, blumea balsamifera extract, kaempferia galanga extract, coriander extract, coriandrum sativum extract, Citrus sinensis extract, lavender extract, Lavandula angustifolia extract, bay laurel extract, sweet basil extract, Ocimum basilicum extract, ocimum tenuiflorum extract, mint extract, Mentha piperita extract, Mentha spicata extract, mentha haplocalyx extract, citronella oil extract, rose oil extract, palmarosa oil extract, geranium extract, cymbopogon citratus extract, corymbia citriodora extract, prunus mandschurica extract, apple tree leaf extract, cinnamon bark extract, strawberry extract, angelica sinensis extract, acai oil extract, Mangifera indica extract, fumaria officinalis extract, rumex japonicus extract, guaiacwood extract, guaiacum officinale extract, guaiacum sanctum extract, lemongrass extract, citrus oil extract, citrus bergamia extract, vanilla planifolia extract, vanilla tahitensis extract, vanilla pompona extract, Theobroma cacao extract, pomegranate extract, myrciaria dubia extract, houttuynia cordata extract, sea lettuce extract, ulva compressa extract, agathosma betulina extract, mentha canadensis extract, eclipta prostrate extract, calendula extract, silybum marianum extract, cydonia oblonga extract, Oenothera biennis extract, lepidium meyenii extract, ulmus rubra extract, Olea europaea extract, acmella oleracea extract, Humulus lupulus extract, nicotiana sylvestris extract, jasmine extract, cananga odorata extract, quince extract, olive tree extract, vaccinium oxycoccus extract, vaccinium macrocarpon extract, prickly pear cactus extract, gymnema sylvestre extract, purslane extract, rosa penduline extract, ceratonia siliqua extract, prunus amygdalus extract, prunus dulcis extract, prunus armeniaca extract, Ginkgo biloba extract, avocado extract, Persea americana extract, Camellia sinensis extract, eucalyptus extract, Linum usitatissimum extract, cyamopsis tetragonoloba extract, sea buckthorn extract, Helianthus annuus extract, Simmondsia chinensis extract, limnanthes alba extract, Sesamum indicum extract, azadirachta indica extract, moringa oleifera extract, cedrus atlantica extract, calophyllum extract, calophyllum inophyllum extract, calophyllum tacamahaca extract, Daucus carota extract, Daucus carota sativa extract, euphorbia cerifera extract, candelilla extract, carnauba palm extract, echinacea purpurea extract, Zea mays extract, quercus infectoria extract, arrowroot extract, eurocoma longifolia extract, trigonella foenum-graecum extract, salvia extract, rosemary extract, sage extract, clary sage extract, Oryza sativa extract, Zingiber officinale extract, licorice extract, matricaria recutita extract, oil palm extract, tapioca extract, Vitis vinifera extract, hazelnut tree extract, turnera diffusa extract, violet extract, podocarpus totara extract, raspberry extract, rubus idaeus extract, rubus strigosus extract, wild indigo extract, safflower extract, and apple extract.
The aqueous topical formulation of any of the preceding claims, further comprising sodium hyaluronate.
The aqueous topical formulation of any of the preceding claims, wherein the topical formulation further comprises vitamin E.
The aqueous topical formulation of any of the preceding claims, wherein the topical formulation further comprises coconut oil.
The aqueous topical formulation of any of the preceding claims, wherein the topical formulation further comprises betaine.
The aqueous topical formulation of any of the preceding claims, wherein the topical formulation further comprises arginine.
The aqueous topical formulation of any of the preceding claims, wherein the topical formulation further comprises niacinamide.
The aqueous topical formulation of any of the preceding claims, wherein the topical formulation does not comprise at least one of niacinamide, estrogen, progesterone, paraben, phthalate, sulfate, gluten, fragrance, soy, nut, mineral oil, and formaldehyde;
- and preferably does not comprise niacinamide.
The aqueous topical formulation of any of the preceding claims, wherein the topical formulation further comprises at least one pH adjuster.
The aqueous topical formulation of any of the preceding claims, wherein the topical formulation has a pH ranging from about 3.0 to about 7.5.
The aqueous topical formulation of any of the preceding claims, wherein the topical formulation has an osmolality ranging from about 150 mOsm/kg to about 400 mOsm/kg.
The aqueous topical formulation of any of the preceding claims, wherein the at least one TRPV1 antagonist is chosen from:
- JYL-1421 [N-(4-tert-butylbenzyl)-N′-[3-fluoro-4-(methylsulfonylamino)benzyl]thiourea];
- KJM429 [N-(4-tert-butylbenzyl)-N′-[4-(methylsulfonylamino)benzyl]thiourea];
- A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea];
- BCTC [N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide];
- JNJ-17203212 [4-(3-trifluoromethylpyridin-2-yl) piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide];
- SB-705498 [N-(2-bromophenyl)-N′—[(I-1-(5-trifluoromethyl-2-pyridyl)68yridine68ne-3-yl)]urea];
- SB-366791 [4′-Chloro-3-methoxycinnamanilide];
- AMG-9810 [I-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acrylamide];
- AMG-2674 [3-Amino-5-[[2-[(2-methoxyethyl)amino]-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2 (1H)-quinoxalinone];
- Capsazepine;
- MK-2295 [6-(I-4-(6-(4-fluorophenyl)-2-(I-2-methylpyrrolidin-1-yl)pyrimidin-4-yl)-3-methylpiperazin-1-yl)-5-methylnicotinic acid];
- Ruthenium red;
- RRRRWW—NH2;
- Methoctramine;
- AG-489;
- AG-505;
- DD-161515 [N-[2-(2-(N-methylpyrrolidinyl)ethyl]glycyl]-[N-[2,4-dichlorophenethyl]glycyl]-N-(2,4-dichlorophenethyl)glycinamide];
- DD-191515 [[N-[3-(N,N-diethylamino) propyl]glycyl]-[N-[2,4-dichlorophenethyl]glycyl]-N-(2,4-dichlorophenethyl)glycinamide];
- A-784168 [1-[3-(trifluoromethyl)69yridine-2-yl]-N-[4-(trifluoromethylsulfonyl)phenyl]-1,2,3,6-tetrahydropyridine-4-carboxamide];
- A-795614 [N-1H-indazol-4-yl-N′-[(1R)-5-piperidin-1-yl-2,3-dihydro-1H-inden-1-yl]urea];
- AMG-0347 [I—N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-3-(2-(piperidin-1-yl)-6-(trifluoromethyl)69yridine-3-yl)acrylamide];
- AMG-517 [N-(4-[6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yloxy]-benzothiazol-2-yl)-acetamide I];
- Pentapeptide-59;
- Mariliance;
- Sensityl;
- resiniferatoxin,
- SYMSITIVE 1609 [4-tertiary butyl cyclohexane],
- Apritone [2-[(2E)-3,7-dimethyl-2,6-octadien-1-yl]cyclopentanone;
- (−)-bornyl acetate;
- hydroxycitronellal [(7-hydroxy-3,7-dimethyloctanal];
- methyl N,N-dimethylanthranilate;
- 2-ethoxy-3-ethylpyrazine;
- L-piperitone;
- isobornyl isobutyrate;
- 4-acetoxy-2,5-dimethyl-3 (2H)-furanone;
- tripropylamine;
- dihydrojasmone [3-methyl-2-pentylcyclopent-2-en-1-one];
- 1-methyl-2-pyrole carboxaldehyde;
- 3-octyl acetate;
- 2-methylbutyl isovalerate;
- jasminone (2-(trans-2-pentenyl)cyclopentanone);
- piperonyl isobutyrate;
- phenoxyethyl propionate;
- vanillin propylene glycol acetate;
- octenyl cyclopentanone;
- butyl isobutyrate;
- guaiacwood oil;
- tetrahydro-4-methyl-2-(2-methyl-1-propenyl)-2H pyran;
- and
- 4-tert-butyl cyclohexanol.
The aqueous topical formulation of any of the preceding claims, wherein the at least one TRPV1 antagonist is pentapeptide-59.
The aqueous topical formulation of any of the preceding claims, wherein the formulation is in a form chosen from:
- emulsion, gel, foam, serum, or lotion for feminine intimate areas;
- bath milk;
- bath soak;
- body mist;
- or emulsion, foam, serum or lotion for the body.
A method of treating at least one symptom of menopause in a subject suffering therefrom, comprising topically administering to the subject an effective amount of a formulation of any one of the preceding claims.
An aqueous topical serum comprising water, pentapeptide-59, lecithin, shea butter, phenethyl alcohol, ethylhexylglycerin, maltodextrin, propylene glycol, xanthan gum, glycerin, hamamelis virginiana leaf extract, akebia quinata extract, sodium benzoate, potassium sorbate, sodium hyaluronate, coconut oil, tocopheryl acetate, and lactic acid.
An aqueous topical serum comprising at least one TRPV1 antagonist, water, propylene glycol, xanthan gum, glycerin, hamamelis virginiana leaf extract, akebia quinata extract, sodium benzoate, potassium sorbate, sodium hyaluronate, coconut oil, tocopheryl acetate, and lactic acid.
An aqueous topical serum comprising at least one TRPV1 antagonist, water, and at least one of hamamelis virginiana leaf extract, akebia quinata extract, and a coconut extract.
An aqueous topical bath milk or bath soak comprising water, sodium lauryl sulfoactetate, hydroxypropyl starch phosphate, pentylene glycol, glycerin, gluconolactone, sodium benzoate, styrene/acrylate copolymer, arginine, sodium phytate, chamomilla recutita flower extract, coconut liquid endosperm, coconut water, coconut fruit juice, rosa damascene flower extract, pentapeptide-59, hydrogenated lecithin, shea butter, phenethyl alcohol, ethylhexylglycerin, maltodextrin, Avena sativa oat kernel flour, tocopherol, and sapindus trifoliatus fruit extract.
An aqueous topical bath milk or bath soak comprising at least one TRPV1 antagonist, water, sodium lauryl sulfoactetate, hydroxypropyl starch phosphate, pentylene glycol, glycerin, gluconolactone, sodium benzoate, styrene/acrylate copolymer, arginine, sodium phytate, chamomilla recutita flower extract, coconut extract, rosa damascene flower extract, Avena sativa oat kernel flour, tocopherol, and sapindus trifoliatus fruit extract.
An aqueous topical serum comprising at least one TRPV1 antagonist, water, and at least one of chamomilla recutita flower extract, coconut extract, rosa damascene flower extract, Avena sativa oat kernel flour, and sapindus trifoliatus fruit extract.
An aqueous topical body mist comprising water, pentylene glycol, palmitoyl-lysyl-valyl-lysine acetate salt, glycerin, sorbitan oleate decylglucoside crosspolymer, Aloe barbadensis leaf juice, pentapeptide-59, hydrogenated lecithin, shea butter, phenethyl alcohol, ethylhexylglycerin, maltodextrin, propylene glycol, menthoxypropanediol, betaine, hydrolyzed quinoa, Cucumis sativus fruit extract, and sodium hyaluronate.
An aqueous topical body mist comprising at least one TRPV1 antagonist, water, water, pentylene glycol, palmitoyl-lysyl-valyl-lysine acetate salt, glycerin, sorbitan oleate decylglucoside crosspolymer, Aloe barbadensis leaf juice, propylene glycol, menthoxypropanediol, betaine, hydrolyzed quinoa, Cucumis sativus fruit extract, and sodium hyaluronate.
An aqueous topical body mist comprising at least one TRPV1 antagonist, water, and at least one of Aloe barbadensis leaf juice, hydrolyzed quinoa, and Cucumis sativus fruit extract.
Dependencies are inferred from the claim text.